首页> Lung cancer (Amsterdam, Netherlands)> Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation.

Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation.

导出 LinkOut

翻译打印收藏纠错

第一作者： Pablo,Moreno-Ruiz

第一单位： Karolinska Institutet, Cancer Center Karolinska, Department of Oncology-Pathology, Stockholm, Sweden.

作者： Pablo,Moreno-Ruiz ^[1] ; Sara,Corvigno ^[2] ; Nienke C,Te Grootenhuis ^[3] ; Linnéa,La Fleur ^[4] ; Max,Backman ^[4] ; Carina,Strell ^[1] ; Artur,Mezheyeuski ^[2] ; Gabriele,Hoelzlwimmer ^[5] ; Christian,Klein ^[6] ; Johan,Botling ^[4] ; Patrick,Micke ^[4] ; Arne,Östman ^[7]

作者单位： Karolinska Institutet, Cancer Center Karolinska, Department of Oncology-Pathology, Stockholm, Sweden. ^[1] Karolinska Institutet, Cancer Center Karolinska, Department of Oncology-Pathology, Stockholm, Sweden; Uppsala University, Genetics and Pathology, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala, Sweden. ^[2] University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, Groningen, The Netherlands. ^[3] Uppsala University, Genetics and Pathology, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala, Sweden. ^[4] Roche Innovation Center Munich Penzberg, Germany. ^[5] Roche Innovation Center Zurich, Schlieren, Switzerland. ^[6] Karolinska Institutet, Cancer Center Karolinska, Department of Oncology-Pathology, Stockholm, Sweden. Electronic address: Arne.Ostman@ki.se. ^[7]

关键词 Biomarkers CD8 FAP Fibroblast Non–small-cell lung cancer PDGFβR Stroma α-SMA